In a double blind placebo-controlled cross-over study the effect of cilostazol on aura induction and endothelial response is tested in patient with migraine with aura.
Migraine with aura is associated to an increased risk of stroke. The mechanism behind such increased risk is not fully understood. Cilostazol induce headache and migraine in migraine patients and is used as secondary prevention of stroke. The effect on aura induction is not known. We investigate the aura inducing potential of cilostazol and associated changes in endothelial function.
- Cilostazol (Pletal®)Drug
Intervention Desc: Single oral administration of active or placebo one week apart ARM 1: Kind: Experimental Label: Active Description: Cilostazol 200 mg single dose
- Placebo Drug
ARM 1: Kind: Experimental Label: Placebo Description: Placebo capsule
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Basic Science
- Intervention: Crossover Assignment
|Type||Measure||Time Frame||Safety Issue|
|Secondary||Endothelial response||3 hours||No|
- Herlev Hospital Lead